Literature DB >> 4147119

Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison.

W M Wardell.   

Abstract

Mesh:

Substances:

Year:  1973        PMID: 4147119     DOI: 10.1002/cpt1973145773

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  8 in total

1.  Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.

Authors:  N S Rawson
Journal:  CMAJ       Date:  2000-02-22       Impact factor: 8.262

2.  Examining the determinants of drug launch delay in pre-TRIPS India.

Authors:  Saradindu Bhaduri; Thomas Brenner
Journal:  Eur J Health Econ       Date:  2012-09-09

3.  Editorial: A remarkable attempt.

Authors:  F Gross
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

4.  Drug lag and key regulatory barriers in the emerging markets.

Authors:  Harriet Wileman; Arun Mishra
Journal:  Perspect Clin Res       Date:  2010-04

5.  The FDA and the COVID-19: A political economy perspective.

Authors:  Raymond J March
Journal:  South Econ J       Date:  2021-02-28

6.  Drug Lag for Inflammatory Bowel Disease Treatments in the East and West.

Authors:  Shinji Okabayashi; Taku Kobayashi; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2018-10-05

7.  Public policy and pharmaceutical innovation.

Authors:  H G Grabowski
Journal:  Health Care Financ Rev       Date:  1982-09

8.  Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.

Authors:  Inhye Cho; Euna Han
Journal:  Int J Environ Res Public Health       Date:  2022-03-01       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.